ClinicalTrials.gov lists 6 registered trials of TRH: 2 recruiting or about to, 0 running, 2 completed, 2 with results posted. Recruiting sites are in China. The largest is LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer (568 people).
Recruiting120 peopleRandomizedChaoxi Zhou2025-05-01 → 2027-04-28🇨🇳 China
Studying: Ascending Colon Cancer, Proximal Transverse Colon Cancer · NCT07207317
About this trial
The aim of this clinical trial is to compare the short- and long-term outcomes of laparoscopic ileocecal reconstruction right hemicolectomy (LIRRH) with those of traditional laparoscopic right hemicolectomy (TRH) for ascending and proximal transverse colon cancer.
The goal of this clinical trial is to compare the long-term outcomes of Laparoscopic Ileocecal-Sparing Right Hemicolectomy(LISH) compared to traditional laparoscopic right hemicolectomy(TRH) in the treatment of hepatic flexure colon cancer and proximal transverse colon cancer.
This study will determine the safety and activity of a new formulation of thyrotropin-releasing hormone (TRH), a drug used for diagnosing and evaluating patients with certain thyroid gland abnormalities. Normal thyroid gland function depends on proper chemical signaling between the thyroid gland, the hypothalamus (the part of the brain where TRH is made), and the pituitary (another part of the brain). The TRH test helps assess this interaction. Production of the only FDA-approved preparation of TRH was stopped in July 2002. As a result, to have a continuous source of TRH available for NIH clin…
WithdrawnPhase 1Memorial Sloan Kettering Cancer Center2021-04-27 → 2023-02-15
Studying: Thyroid Cancer · NCT04868045
About this trial
The purpose of this study is to find out whether people who have had thyroid cancer develop resistance to treatment with thyroid hormones after having received high doses of thyroid drugs for many years.
TerminatedPhase 211 peopleRandomizedUConn Health2006-12 → 2010-02🇺🇸 United StatesResults posted
Studying: Cancer-related Fatigue · NCT00790296
About this trial
The primary objective of the study is to evaluate thyrotropin releasing hormone (TRH) as a treatment for cancer-related fatigue.
The central hypothesis of this pilot study is that TRH is more efficacious than placebo in alleviating cancer-related fatigue in patients with breast or prostate cancer.
Registered trials include ones that haven't published results yet. Trials are matched on the compound's name and code names (TRH) in the listed interventions.